Page 6

19544GA

126 Kidney Cancer Journal T A B L E O F C O N T E N T S Advances in Treatment of RCC: Chronicling 25 Years of Progress he timeline featured above encapsulates the progress made in the treatment of renal cell carcinoma (RCC) since 1992 when options for therapy were not only limited but associated with toxicity that deterred many patients from accepting available regimens, including interleukin-2 (IL-2) and interferon. The slide developed by James Hsieh, MD, who directs the Memorial Sloan Kettering’s Translational Kidney Cancer Research Program, dramatically illustrates how far and where new directions in therapy have gone. We have seen at various points in the timeline how management strategies have ushered in what might be called “new eras” in treatment. And, yet, as good as this timeline is in chronicling the advances made in the treatment of the disease, it is important to consider the twists and turns within these 25 years, the expectations raised by innovative approaches to the disease and yes, the setbacks and disappointments after the life cycle of various drugs revealed how challenging RCC remains and Editorial Mission The purpose of Kidney Cancer Journal is to serve as a comprehensive resource of information for physicians regarding advances in the diagnosis and treatment of renal cell carcinoma. Content of the journal focuses on the impact of translational research in oncology and urology and also provides a forum for cancer patient advocacy. Kidney Cancer Journal is circulated to medical oncologists, hematologist-oncologists, and urologists. Editor-in-Chief Robert A. Figlin, MD, FACP Steven Spielberg Family Chair in Hematology Oncology Professor of Medicine and Biomedical Sciences Director, Division of Hematology Oncology Deputy Director, Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center Medical Advisory Board Michael B. Atkins, MD Deputy Director Lombardi Comprehensive Cancer Center Professor of Oncology and Medicine, Georgetown University Medical Center Washington, DC Ronald M. Bukowski, MD Emeritus Staff & Consultant CCF Taussig Cancer Center Professor of Medicine CCF Lerner College of Medicine of CWRU Cleveland, Ohio Robert J. Motzer, MD Attending Physician Memorial Sloan-Kettering Cancer Center New York, NY Christopher G. Wood, MD, FACS Douglas E. Johnson, MD Professorship Professor & Deputy Chairman Department of Urology M.D. Anderson Cancer Center Houston, Texas Nurse Advisory Board Nancy Moldawer, RN, MSN Nursing Director Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute Los Angeles, California Laura Wood, RN, MSN, OCN Renal Cancer Research Coordinator Cleveland Clinic Taussig Cancer Center Cleveland, Ohio Patient Advocate William P. Bro Chief Executive Officer Kidney Cancer Association Publishing Staff Stu Chapman, Executive Editor Jenny Chapman, Director, Business Development Gloria Catalano, Production Director Michael McClain, Design Director Business and Administration Office 515 E. 88th Street, Suite 1L New York, N Y 10128 Editorial Offices Genitourinary Publishing 2557 Tulip St. Sarasota, FL 34239 Tel: (516) 356-5006 © Copyright 2016 Genitourinary Publishing. All rights reserved. None of the contents may be reproduced in any form without the permission of the publisher. About the Cover Dysregulation of the von Hippel-Lindau protein in RCC leads to activation of three key signaling pathways (MET, AXL, and VEGFR) targeted by cabozantinib, which was recently approved for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy. 128 Journal Club 129 Medical Intelligence 130 Roundtable Discussion on CABOSUN Trial 134 S-TRAC Trial and Its implications E D I TOR ’ S M E M O (continued on page 139) T


19544GA
To see the actual publication please follow the link above